These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 2436132)
21. Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study. Salloum E; Doria R; Farber LR; Roberts KB; Cooper DL Cancer J Sci Am; 1995; 1(4):267-73. PubMed ID: 9166487 [TBL] [Abstract][Full Text] [Related]
22. Chemotherapy strategies to improve the control of Hodgkin's disease: the Richard and Hinda Rosenthal Foundation Award Lecture. Bonadonna G Cancer Res; 1982 Nov; 42(11):4309-20. PubMed ID: 6181867 [TBL] [Abstract][Full Text] [Related]
24. Corticosteroid drugs: their role in oncological practice. Lowenthal RM; Jestrimski KW Med J Aust; 1986 Jan; 144(2):81-5. PubMed ID: 2417096 [No Abstract] [Full Text] [Related]
25. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. Seymour JF; Pro B; Fuller LM; Manning JT; Hagemeister FB; Romaguera J; Rodriguez MA; Ha CS; Smith TL; Ayala A; Hess M; Cox JD; Cabanillas F; McLaughlin P J Clin Oncol; 2003 Jun; 21(11):2115-22. PubMed ID: 12775737 [TBL] [Abstract][Full Text] [Related]
26. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study. Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131 [TBL] [Abstract][Full Text] [Related]
28. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
29. [Primary treatment of advanced Hodgkin's disease]. Illés A; Udvardy M; Molnár Z Orv Hetil; 2005 Jan; 146(5):195-202. PubMed ID: 15773586 [TBL] [Abstract][Full Text] [Related]
30. European experience with ifosfamide in lymphomas. von Kalle AK; Schaadt M; Diehl V Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184 [TBL] [Abstract][Full Text] [Related]
31. [Adriamycin for the treatment of non HOdgkin's lymphomas (author's transl)]. Parlier Y; Gorin NC; Stachowiak J; Najman A; Duhamel G Sem Hop; 1981 Nov 8-25; 57(41-42):1685-90. PubMed ID: 6272402 [TBL] [Abstract][Full Text] [Related]
32. [Results of cytostatic polychemotherapy in non-Hodgkin lymphomas]. Kratzer H; Hehenwarter W; Denz H; Bliem J; Tschurtschenthaler G; Nitsche D; Huber H; Michlmayr G Wien Klin Wochenschr; 1983 Aug; 95(16):558-62. PubMed ID: 6689099 [TBL] [Abstract][Full Text] [Related]
33. [Treatment of malignant lymphoma in childhood]. Hattori T; Ishikawa Y; Nishi M; Nakadate H; Hatae Y; Takeda T Rinsho Ketsueki; 1985 Jan; 26(1):1-6. PubMed ID: 2582160 [No Abstract] [Full Text] [Related]
34. Influence of chemotherapy on the phagocytic activity of mononuclear cells in patients with Hodgkin's disease. Süss J; Bakács T; Molnár Z Allerg Immunol (Leipz); 1984; 30(4):251-4. PubMed ID: 6084424 [TBL] [Abstract][Full Text] [Related]
35. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis. Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406 [TBL] [Abstract][Full Text] [Related]
36. Acute myeloid leukemia following therapy of Hodgkin's disease with radiotherapy and ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine). Lipton JH; Gospodarowicz M; Reingold S Hematol Oncol; 1996 Mar; 14(1):29-31. PubMed ID: 8613133 [TBL] [Abstract][Full Text] [Related]
37. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Bezjak A; Wells WA; Burns BF; Winter JN; Horning SJ; Dar AR; Djurfeldt MS; Ding K; Shepherd LE; ; J Clin Oncol; 2005 Jul; 23(21):4634-42. PubMed ID: 15837968 [TBL] [Abstract][Full Text] [Related]
38. Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study. Longo DL; Duffey PL; Gribben JG; Jaffe ES; Curti BD; Gause BL; Janik JE; Braman VM; Esseltine D; Wilson WH; Kaufman D; Wittes RE; Nadler LM; Urba WJ Cancer J; 2000; 6(3):146-50. PubMed ID: 10882329 [TBL] [Abstract][Full Text] [Related]